{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:08:27Z","timestamp":1774314507808,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have significantly advanced the treatment of malignant tumors. Tislelizumab, a recombinant humanized anti\u2013programmed death 1 (PD-1) monoclonal antibody, is widely used in the management of advanced cancers. However, like other ICIs, tislelizumab can trigger immune-related adverse events (irAEs). Among irAEs, immune checkpoint inhibitor-associated myocarditis (ICI-associated myocarditis) is rare but life-threatening, underscoring the need for early recognition and intervention. This case report describes a case of highly suspected fulminant myocarditis induced by ICI in a patient with gallbladder adenocarcinoma and intrahepatic cholangiocarcinoma (iCCA) following treatment with tislelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 72-year-old female presented with a 4-h history of palpitations and dyspnea on June 16, 2025. Initial electrocardiography (ECG) revealed ventricular tachycardia (VT), which was successfully terminated with 200\u2005J cardioversion. Subsequent monitoring showed third-degree atrioventricular block (AVB). She had been diagnosed with iCCA and gallbladder adenocarcinoma on May 7, 2025, and had undergone partial hepatectomy and cholecystectomy. She later received intravenous tislelizumab (200\u2005mg) on May 22, 2025, followed by a second 200\u2005mg dose on June 10, with no adverse effects observed during either infusion. Upon admission, investigations revealed no coronary abnormalities on coronary computed tomography, a left ventricular ejection fraction (LVEF) of 42%, markedly elevated cardiac biomarkers [e.g., cardiac troponin I (cTnI) 3.80\u2005\u03bcg\/L], hypoxemia, and 24-h Holter monitoring that documented short episodes of VT and third-degree AVB. Based on the temporal relationship to ICI therapy, the clinical presentation, laboratory and imaging findings, and the exclusion of alternative etiologies, fulminant ICI-associated myocarditis was highly suspected. Treatment included noninvasive mechanical ventilation, temporary pacing, high-dose methylprednisolone, intravenous immunoglobulin, antiarrhythmic agents, and heart failure (HF) management. On hospital day 4, the patient's symptoms had improved, although third-degree AVB persisted. On hospital day 15, her atrioventricular conduction had improved from third-degree to first-degree block, with cardiac biomarkers decreasing to much lower levels. On hospital day 18, repeat transthoracic echocardiography (TTE) showed an LVEF of 49% with generalized hypokinesis of the left ventricular wall, and a repeat ECG revealed first-degree AVB, complete right bundle branch block, and left anterior fascicular block. She was discharged on the same day. During the subsequent 2-month follow-up after discharge, the patient remained clinically stable but developed symptoms of muscle weakness, for which she did not seek further medical evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICI-associated myocarditis is characterized by a low incidence but carries a high risk of fatal outcomes. Early recognition of severe cases and timely intervention can substantially improve prognosis. In this case, fulminant myocarditis related to the ICI tislelizumab was highly suspected but not pathologically confirmed, as cardiac magnetic resonance imaging and endomyocardial biopsy were not performed. Despite this limitation, the case may still provide a useful clinical reference for the diagnosis and management of severe ICI-associated myocarditis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1726826","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:39:32Z","timestamp":1770964772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Highly suspected fulminant myocarditis induced by the immune checkpoint inhibitor tislelizumab: a case report with third-degree atrioventricular block and recurrent ventricular tachycardia"],"prefix":"10.3389","volume":"13","author":[{"given":"Junru","family":"Qu","sequence":"first","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyi","family":"Su","sequence":"additional","affiliation":[{"name":"Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuquan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/cac2.12587","article-title":"Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies","volume":"44","author":"Sun","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.Cd-22-1180","article-title":"Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/jci145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"ehaf315","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","author":"Power","year":"2025","journal-title":"Eur Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (estro) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/circulationaha.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/s1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jacc.2024.11.023","article-title":"ACC\/AHA\/ASE\/HFSA\/HRS\/SCAI\/SCCT\/SCMR 2025 appropriate use criteria for implantable cardioverter-defibrillators, cardiac resynchronization therapy, and pacing","volume":"85","author":"Russo","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40959-023-00185-y","article-title":"Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis","volume":"9","author":"O\u2019Shea","year":"2023","journal-title":"Cardiooncology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jaccas.2022.04.020","article-title":"Checkpoint immunotherapy-induced myocarditis and encephalitis complicated with complete AV block: not all hope is lost","volume":"4","author":"Lorente-Ros","year":"2022","journal-title":"JACC Case Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103003","DOI":"10.1016\/j.cpcardiol.2025.103003","article-title":"Atrioventricular block and conduction disorders induced by icis: individual patient data systematic review: \u201cconduction disorders induced by ICIS\u201d","volume":"50","author":"Pascalis","year":"2025","journal-title":"Curr Probl Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jaccao.2023.09.004","article-title":"Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: contemporary 1-year outcomes","volume":"5","author":"Itzhaki Ben Zadok","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.mayocp.2024.12.017","article-title":"Characterization of cardiovascular events and prognosis in immune checkpoint inhibitor-related myocarditis","volume":"100","author":"Pereyra Pietri","year":"2025","journal-title":"Mayo Clin Proc"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1726826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:39:33Z","timestamp":1770964773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1726826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":20,"alternative-id":["10.3389\/fcvm.2026.1726826"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1726826","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1726826"}}